Baxter International Inc.
Baxter International Inc.
Your view on BAX
Overview
What the company does, where it operates, and who runs it.
About Baxter International Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Andrew P. Hider
- Headquarters
- One Baxter Parkway, Deerfield, IL, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Andrew P. Hider
- Headquarters
- One Baxter Parkway, Deerfield, IL, US
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision.
The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.
Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Baxter International Inc. from FRC's valuation model, read against the market price. BAX last traded at $25.54; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Baxter International Inc.. Starting points for Baxter International Inc.: EPS -$1.40, beta 0.67 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Baxter International Inc.. Baxter International Inc. paid $0.04 per share over the last year — a 0.2% yield at the current $25.54 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Baxter International Inc.. Trailing twelve-month EPS for Baxter International Inc. stands at -$1.40. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$22.25
average of 8 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy1
- Hold7
- Sell2
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.60 | $0.41 | $2.11 | $2.04 |
| Low estimate | $0.59 | $0.38 | $2.06 | $1.75 |
| High estimate | $0.61 | $0.43 | $2.13 | $2.13 |
| No. of analysts | 10 | 6 | 10 | 10 |
| Year-ago EPS | $0.44 | $0.36 | -$1.751 | — |
| Growth | +35.6% | +14.8% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.09B | $2.76B | $11.72B | $11.97B |
| Low estimate | $3.05B | $2.74B | $11.61B | $11.77B |
| High estimate | $3.10B | $2.78B | $11.75B | $12.04B |
| No. of analysts | 9 | 5 | 11 | 11 |
| Year-ago revenue | $2.97B | $2.70B | $11.24B | — |
| Growth | +3.8% | +2.3% | +4.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Baxter International Inc.. Baxter International Inc. has reported as a listed company since 1981. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- DVADaVita Inc.Medical - Care Facilities$11.0B
- FMSFresenius Medical Care AG & Co. KGaAMedical - Care Facilities$11.7B
- ICUIICU Medical, Inc.Medical - Instruments & Supplies$4.5B
- INFUInfuSystem Holdings, Inc.Medical - Devices$296M
- RMTIRockwell Medical, Inc.Drug Manufacturers - Specialty & Generic$27M
More Medical - Instruments & Supplies companies
- MHUAFMeihua International Medical Technologies Co., Ltd.OTC$6M
- MLSSMilestone Scientific Inc.AMEX$27M
- MMSIMerit Medical Systems, Inc.NASDAQ$5.2B
- NAN.AXNanosonics LimitedASX
- NEPHNephros, Inc.NASDAQ$33M
- NNCSFNanosonics LimitedOTC$698M
- NNNNAnbio Biotechnology Class A Ordinary SharesNASDAQ$170M
- NPRRFNipro CorporationOTC$1.3B
- NVSTEnvista Holdings CorpNYSE$3.9B
- NXGLNEXGEL, Inc.NASDAQ$2M
- NXGLWNEXGEL, Inc.NASDAQ$504,035
- OJSYOJsys, Inc.OTC$454,285
ETFs holding Baxter International Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.02%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.02%
- VBVanguard Small-Cap ETF$76.9B in assets0.15%
- RSPInvesco S&P 500 Equal Weight ETF$101.8B in assets0.21%
- PZLVPzena U.S. Large Cap Value ETF$71M in assets5.00%
- ADPVAdaptiv Select ETF$173M in assets3.94%
- IHIiShares US Medical Devices ETF$4.0B in assets1.68%
- FPAGFPA Global Equity ETF$673M in assets1.54%
Largest holders first, then the funds most concentrated in BAX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Baxter International Inc., and how their positions are changing. At a $13.21B market value, institutional positions materially move Baxter International Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Baxter International Inc. executives and directors. Shares of Baxter International Inc. have traded between $17.40 and $37.74 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Baxter International Inc.. Baxter International Inc. is a $13.21B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Baxter International Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Baxter International Inc.. Coverage tracks Baxter International Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Baxter International Inc.